vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track

vTv Therapeutics Inc.

Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.
Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.
Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.
R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M).

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

vTv Therapeutics Inc. reported first quarter ended March 31, 2026 results: revenue $36,839, net income Net income attributable to vTv shareholders for the three months ended March 31, 2026, was $24.1 million, EPS $1.94 and $1.65 per basic and diluted share, respectively.

Period: first quarter ended March 31, 2026
Revenue: $36,839
Net income: Net income attributable to vTv shareholders for the three months ended March 31, 2026, was $24.1 million
EPS: $1.94 and $1.65 per basic and diluted share, respectively
Result: reported results

Exact text from the filing

$ 89,899 vTv Therapeutics Inc. Condensed Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended March 31, 2026 2025 (Unaudited) Revenue $ 36,839 $ — Operating expenses: Research and development 8,978 2,830 General and administrative 4,598 3,673 Total operating expenses 13,576 6,503 Operating income/(loss) 23,263 (6,503)

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.